Showing all entries tagged with »Biotech«
August 24, 2023
In this article, Michael N. Abrams and Alexander Natz discuss the current policy initiatives from Europe and the U.S., similarities between them, and implications for the pharmaceutical sector and their standing in a competitive global market. For years, lawmakers have… read more
May 3, 2023
In this guest blog, Toon Digneffe, EUCOPE Board Member & Head of Public Affairs and Partnerships – Europe & Canada at Takeda, reflects on the EU Pharmaceutical Package and highlights the importance of multi-stakeholder partnerships to build a sustainable rare… read more
December 19, 2022
Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the General Pharmaceutical Legislation… read more
June 2, 2020
EUCOPE asks the European Commission to put research at the heart of its Pharmaceutical Strategy The European Commission’s Pharmaceutical Strategy for Europe must: Provide ambitious measures to foster research in rare diseases and other disease areas for which we currently… read more
May 15, 2020
The 10th European Conference on Rare Diseases (ECRD), the largest patient-led event on rare diseases and orphan products, presented an excellent opportunity for exchange among the patient community and experts from various backgrounds. Bringing the perspective of OMP focused small… read more